Grace Therapeutics, Inc. (GRCE) Form 8-K — Aug 6, 2026
Grace Therapeutics (GRCE) raised approximately $10 million in gross proceeds through a private placement, selling 4,761,904 shares of common stock at $2.10 per share to institutional and accredited investors. The offering closed on August 6, 2026. Craig-Hallum Capital Group LLC acted as placement agent. Under the registration rights agreement, the company must file a resale registration statement within 30 days of closing and use reasonable best efforts to make it effective promptly — within 60 days if the SEC reviews the filing, or within five business days after being notified it will not be reviewed.
Key figures
- Gross Proceeds
- approximately $10 million
- Offering Price
- 2.1
- Shares Offered
- 4761904
- Closing Date
- 2026-08-06
- Agreement Date
- 2026-08-04
- Restricted Period
- later of 90 days from Closing Date or 30 days after registration statement effectiveness
- Placement Agent Fees
- customary placement fees payable to Craig-Hallum (amount not disclosed)
- Effectiveness Deadline
- earlier of the 60th calendar day after initial filing (if SEC reviews) or the 5th business day after SEC no-review notice
- Registration Filing Deadline
- no later than 30 days after the Closing Date
Price after filing
Close on the filing date to close N calendar days later (from $2.18). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.